This invention is based on the discovery that the type II TGF-β receptor (RII) is a cancer suppressor gene which is genetically inactivated (mutated) in approximately 25% of colon cancers, including nearly all colon cancers of the class identified as mutator/microsatellite instability/RER. Methods are provided for detecting inactivation of RII for use in cancer diagnosis or prognosis.
Case Western Reserve University; Medical College of Ohio
435/6.1; 435/7.1; 435/7.2; 435/7.21; 435/7.23; 436/503; 436/811
These materials are free of copyright restrictions and are in the public domain within the United States only. The USPTO reserves the right to assert copyright protection internationally.
The University of Toledo
University of Toledo Libraries
Markowitz, Sanford D.; Brattain, Michael G.; and Willson V, James K., "Cancer diagnosis prognosis and therapy based on mutation of receptors for transforming growth factor β and homologous growth controlling factors" (1999). University of Toledo U.S. Patents. 139.